Evaluating the MBVP Chemotherapy Schedule Followed by Consolidating Radiotherapy in Non-AIDS Related Primary Central Nervous System Lymphoma (NAPCL)
OBJECTIVES: I. Determine the efficacy of methotrexate and cytarabine chemotherapy in
combination with whole-brain radiation therapy for patients with non-AIDS related primary
central nervous system lymphoma. II. Assess the response rate and safety of this
OUTLINE: Patients receive the first course of chemotherapy as soon as possible after
diagnosis and staging. Methotrexate (MTX) IV is administered over 40-60 minutes on days 1
and 15. Cytarabine (AraC) is administered intrathecally on days 1 and 15. The second course
of chemotherapy begins on day 29 or after bone marrow recovery. Radiation therapy begins no
later than 3 weeks after completing chemotherapy. Patients are followed until death.
PROJECTED ACCRUAL: A maximum of 50 patients will be accrued.
Primary Purpose: Treatment
Philip Poortmans, MD, PhD
Dr. Bernard Verbeeten Instituut
United States: Federal Government